Glucocorticoid therapy of spinal cord injury

Annals of the New York Academy of Sciences

Volumn 743, Issue , 1994, Pages 241-263

  Young, W ^a   Kume Kick, J ^a   Constantini, S ^a   Moorjani, B ^a   Harvey, M ^a   Harding, C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; SCAVENGER;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NERVE CELL NECROSIS; SPINAL CORD INJURY;

EID: 0028578028     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1994.tb55796.x     Document Type: Conference Paper

References (243)

1. 1 YOUNG, W. & M. B. BRACKEN, 1992. The second national acute spinal cord injury study. J. Neurotrauma. 9: S429–451.
2. 2 BRACKEN, M. B. & T. R. HOLFORD 1993. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long‐tract neurological function in NASCIS 2. J Neurosurg. 79: 500–507.
3. 3 BRACKEN, M. B., M. J. SHEPARD, W. F. J. COLLINS, T. R. HOLFORD, D. S. BASKIN, H. M. EISENBERG, E. FLAMM, S. L. LEO, J. C. MAROON, L. F. MARSHALL, P. PEROT, J. PIEPMEIER, V. SONNTAG, F. C. WAGNER, J. E. WILBERGER, H. R. WINN & W. YOUNG 1992. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1‐year follow‐up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 76: 23–31.
4. 4 BRACKEN, M. B. 1991. Treatment of acute spinal cord injury with methylprednisolone: Results of a multicenter, randomized clinical trial. J Neurotrauma. 8: S47–50 ; discussion S51–52.
5. 5 BRACKEN, M. B., M. J. SHEPARD, W. F. COLLINS, T. R. HOLFORD, D. S. BASKIN, H. M. EISENBERG, E. S. FLAMM, L. LEO‐SUMMERS, J. MAROON, L. F. MARSHALL, P. PEROT, J. PIEPMEIER, V. SONNTAG, F. C. WAGNER, J. E. WILBERGER & H. R. WINN 1990. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal‐cord injury: Results of the Second National Acute Spinal Cord Injury Study. New Engl. J Med. 322: 1405–1411.
6. 6 MUNCK, A. & K. LEUNG 1977. Glucocorticoid receptors and mechanisms of action. In Receptors and Mechanism of Action of Steroid Hormones. J. R. Pasqualini, Ed.: 311–319. New York: Marcel Dekker.
7. 7 HER, E., N. REISS, P. BRAQUET & U. ZOR 1991. Characterization of glucocorticoid inhibition of antigen‐induced inositolphosphate formation by rat basophilic leukemia cells: Possible involvement of phosphatases. Biochim. Biophys. Acta 1133: 63–72.
8. 8 TSURUFIJI, S., K. SUGIO & F. TAKEMASA 1979. The role of glucocorticoid receptors and gene expression in the anti‐inflammatory action of dexamethasone. Nature (Lond.). 280: 408–410.
9. 9 RUSSO‐MARIE, F., M. PAING & D. DUVAL 1979. Involvement of glucocorticoid receptors in steroid‐induced inhibition of prostaglandin secretion. J Biol. Chem. 254: 8498–8504.
10. 10 BLACKWELL, G. J., R. CARNUCCIO, M. DI ROSA, R. J. FLOWER, C. S. J. LANGHAM, L. PARENTE, P. PERSICO, N. C. RUSSELL‐SMITH & D. STONE 1982. Glucocorticoids induce the formation and release of anti‐inflammatory and anti‐phospholipase effect of glucocorticoids. Nature (Lond.). 287: 147–149.
11. 11 FLOWER, R. J. 1988. Lipocortin and the mechanism of action of the glucocorticoids. Br. J Pharmacol. 94: 987–1015.
12. 12 VIOLETTE, S. M., I. KING, J. L. BROWNING, R. B. PEPINSKY, B. P. WALLNER & A. C. SARTORELLI 1990. Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J Cell. Physiol. 142: 70–77.
13. 13 MARIDONNEAU, P. I., M. ERRASFA & M. F. RUSSO 1989. Inhibition of O 2 ‐generation by dexamethasone is mimicked by lipocortin I in alveolar macro‐phages. J. Clin. Invest. 83: 19361940.
14. 14 YU, Z. Y., O. WRANGE, J. BOETHIUS, A. HATAM, L. GRANHOLM & J. A. GUSTAFSSON 1981. A study of glucocorticoid receptors in intracranial tumors. J Neurosurg. 55: 757–760.
15. 15 CLARK, C. R., N. J. MACLUSKY & F. NAFTOLIN 1981. Glucocorticoid receptors in the spinal cord. Brain Res. 217: 412–415.
16. 16 HARFSTRAND, A., K. FUXE, A. CINTRA, L. F. AGNATI, I. ZINI, A. C. WIKSTROM, S. OKRET, Z. Y. YU, M. GOLDSTEIN, H. STEINBUSCH, A. VERHOFSTAD & J. A. GUSTAFSSON 1986. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc. Natl. Acad. Sci. USA 83: 9779–9783.
17. 17 HUANG, W., C. L. CHOI, Z. YANG, D. C. COPOLOV & A. T. LIM 1991. Forskolin‐induced immunoreactive atrial natriuretic peptide (ANP) secretion and pro‐ANP messenger ribonucleic acid expression of hypothalamic neurons in culture: Modulation by glucocorticoids. Endocrinology 128: 2591–2600.
18. 18 ARJAMAA, O., O. VUOLTEENAHO, T. TASKINEN, M. TUOMINEN & J. LEPPALUOTO 1990. Adrenal cortex contributes to the regulation of NaCl‐stimulated ANP release in the rat. Acta Physiol. Scand. 139: 355–360.
19. 19 DAMJANCIC, P. & H. VIERHAPPER 1990. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp. Clin. Endocrinol. 95: 315–321.
20. 20 DAYANITHI, G. & F. A. ANTONI 1990. Atriopeptins are potent inhibitors of ACTH secretion by rat anterior pituitary cells in vitro: Involvement of the atrial natriuretic factor receptor domain of membrane‐bouind guanylyl cyclase. J Endocrinol. 125: 39–44.
21. 21 FULLERTON, M. J., Z. S. KROZOWSKI & J. W. FUNDER 1991. Adrenalectomy and dexamethasone administration: Effect on atrial natriuretic peptide synthesis and circulating forms. Mol. Cell. Endocrinol. 82: 33–40.
22. 22 ARGENTIN, S., Y. L. SUN, I. LIHRMANN, T. J. SCHMIDT, J. DROUIN & M. NEMER 1991. Distal cis‐acting promoter sequences mediate glucocorticoid stimulation of cardiac atrial natriuretic factor gene transcription. J Biol. Chem. 266: 23315–23322.
23. 23 SAUER, J., M. RUPPRECHT, E. ARZT, G. K. STALLA & R. RUPPRECHT 1993. Glucocorticoids modulate soluble interleukin‐2 receptor levels in vivo depending on the state of immune activation and the duration of glucocorticoid exposure. Immunopharmacology 25: 269–276.
24. 24 ALMAWI, W. Y., E. T. HADRO & T. B. STROM 1991. Evidence that glucocorticoid‐mediated immunosuppressive effects do not involve altering second messenger function. Transplantation 52: 133–140.
25. 25 BAILEY, J. M. 1991. New mechanisms for effects of anti‐inflammatory glucocorticoids. Biofactors 3: 97–102.
26. 26 MITCHELL, D. R., T. W. JACKSON & K. W. LYLES 1991. Effects of shortterm administration of glucocorticoids on bone metabolism in healthy elderly men. J Am. Geriatr. Soc. 39: 1179–1182.
27. 27 OIKARINEN, A., P. AUTIO, J. VUORI, K. VAANANEN, L. RISTELI, U. KIISTALA & J. RISTELI 1991. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and amino‐terminal propeptide of type III procollagen. Br. J Dermatol. 126: 172–178.
28. 28 DEFRANCO, D. B., M. QI, K. C. BORROR, M. J. GARABEDIAN & D. L. BRAUTIGAN 1991. Protein phosphatase types 1 and/or 2A regulate nucleocytoplasmic shuttling of glucocorticoid receptors. Mol. Endocrinol. 5: 1215–1228.
29. 29 ZOR, U., E. HER, P. BRAQUET, E. FERBER & N. REISS 1991. A novel mechanism of glucocorticosteroid (GC) action in suppression of phospholipase A2 (PLA2) activity stimulated by Ca 2+ ionophore A23187: Induction of protein phosphatases. Adv. Prostaglandin Thromboxane Leukot. Res. 21A: 265–271.
30. 30 HER, E. & U. ZOR 1991. Glucocorticoid inhibition of antigen‐induced inositol phosphate formation: Possible involvement of phosphatases. J Basic Clin. Physiol. Pharmacol. 2: 217–222.
31. 31 BOLLEN, M. & W. STALMANS 1992. The structure, role, and regulation of type 1 protein phosphatases. Crit. Rev. Biochem. Mol. Biol. 27: 227–281.
32. 32 KAMALIA, N., C. A. MCCULLOCH, H. C. TENENBAUM & H. LIMEBACK 1992. Direct flow cytometric quantification of alkaline phosphatase activity in rat bone marrow stromal cells. J Histochem. Cytochem. 40: 1059–1065.
33. 33 SOMERS, J. P. & D. B. DEFRANCO 1992. Effects of okadaic acid, a protein phosphatase inhibitor, on glucocorticoid receptor‐mediated enhancement. Mol. Endocrinol. 6: 26–34.
34. 34 KATO, M., D. BRIJLALL, S. A. ADLER, S. KATO & F. HERZ 1992. Effect of hyperosmolality on alkaline phosphatase and stress‐response protein 27 of MCF‐7 breast cancer cells. Breast Cancer Res. Treat. 23: 241–249.
35. 35 SUBRAMANIAM, M., D. COLVARD, P. E. KEETING, K. RASMUSSEN, B. L. RIGGS & T. C. SPELSBERG 1992. Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and proto‐oncogenes in normal human osteoblast‐like cells. J Cell. Biochem. 50: 411–424.
36. 36 SOLTER, P. F., W. E. HOFFMANN, L. L. HUNGERFORD, M. E. PETERSON & J. L. DORNER 1993. Assessment of corticosteroid‐induced alkaline phosphatase isoenzyme as a screening test for hyperadrenocorticism in dogs. J Am. Vet. Med. Assoc. 203: 534–538.
37. 37 OHOKA, Y., Y. NAKAI, M. MUKAI & M. IWATA 1994. Okadaic acid inhibits glucocorticoid‐induced apoptosis in T cell hybridomas at its late stage. Biochem. Biophys. Res. Commun. 197: 916–921.
38. 38 HER, E. & U. ZOR 1992. Glucocorticoid inhibition of antigen‐induced inositol phosphate formation: Possible involvement of phosphatases. J Basic Clin. Physiol. Pharmacol. 2: 217–222.
39. 39 MOYER, M. L., K. C. BORROR, B. J. BONA, D. B. DEFRANCO & S. K. NORDEEN 1993. Modulation of cell signaling pathways can enhance or impair glucocorticoid‐induced gene expression without altering the state of receptor phosphorylation. J Biol. Chem. 268: 22933–22940.
40. 40 HALL, E. D. & T. BAKER 1979. Acute effects of methylprednisolone sodium succinate on spinal reflexes. Exp. Neurol. 63: 476–484.
41. 41 YOUNG, W. & E. S. FLAMM 1982. Effect of high dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg. 57: 667–673.
42. 42 HALL, E. D., M. PLASTER & J. M. BRAUGHLER 1983. Acute cardiovascular response to a single large intravenous dose of methylprednisolone and its effects on the responses to norepinephrine and isoproterenol. Proc. Soc. Exp. Biol. Med. 173: 338–343.
43. 43 ANDRASSY, R. J. & T. DUBOIS 1985. Modified injury severity scale and concurrent steroid therapy: independent correlates of negative nitrogen balance in pediatric trauma. J Pediatr. Surg. 20: 799–802.
44. 44 BRAUGHLER, J. M. & E. D. HALL 1981. Correlation of methylprednisolone pharmacokinetics in cat spinal cord with its effect on (Na + ‐K +)‐ATPase, lipid peroxidation and motor neuron function. J. Neurosurg. 56: 838–844.
45. 45 BRAUGHLER, J. M. & E. D. HALL 1981. Acute enhancement of spinal cord synaptosomal (Na + ‐ K +)‐ATPase activity in cats following intravenous methylprednisolone. Brain Res. 219: 464–469.
46. 46 HALL, E. D. & J. M. BRAUGHLER 1982. Glucocorticoid mechanisms in acute spinal cord injury: A review and therapeutic rationale. Surg. Neurol. 18: 320–327.
47. 47 HALL, E. D. & J. M. BRAUGHLER 1982. Effects of methylprednisolone on spinal cord lipid peroxidation and (Na + ‐K +)‐ATPase activity: Dose response analysis during the first hour after contusion injury in the cat. J. Neurosurg. 57: 247–253.
48. 48 BRAUGHLER, J. M. & E. D. HALL 1982. Pharmacokinetics of methylprednisolone in cat plasma and spinal cord following a single intravenous dose of the sodium succinate ester. Drug Metab. Dispos. 10: 551–552.
49. 49 BRAUGHLER, J. M. & E. D. HALL 1983. Lactate and pyruvate metabolism in injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. J Neurosurg. 59: 256–261.
50. 50 HALL, E. D., D. L. WOLF & J. M. BRAUGHLER 1983. Dose response and time action analysis of the effects of a single large dose of methylprednisolone sodium succinate on post traumatic spinal cord ischemia. J Neurosurg. 58: 1–22.
51. 51 HALL, E. D., D. L. WOLF & J. M. BRAUGHLER 1984. Effects of a single large dose of methylprednisolone sodium succinate on experimental post‐traumatic spinal cord ischemia. Dose‐response and time‐action analysis. J Neurosurg. 61: 124–130.
52. 52 BRAUGHLER, J. M. & E. D. HALL 1984. Effects of multi‐dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg. 61: 290–295.
53. 53 HALL, E. D. & D. C. WOLF 1984. Methylprednisolone preservation of motor nerve function during early degeneration. Exp. Neurol. 84: 715–720.
54. 54 ANDERSON, D. K., R. D. SAUNDERS, P. DEMEDIUK, L. L. DUGAN, J. M. BRAUGHLER, E. D. HALL, E. D. MEANS & L. A. HORROCKS 1985. Lipid hydrolysis and peroxidation in injured spinal cord: Partial protection with methylprednisolone or vitamin E and selenium. Cent. Nerv. Syst. Trauma 2: 257–267.
55. 55 HALL, E. D. 1991. Inhibition of lipid peroxidation in CNS trauma. J Neurotrauma 8: S31–40 ;discussion S41.
56. 56 HALL, E. D. 1992. The neuroprotective pharmacology of methylprednisolone. J Neurosurg. 76: 13–22.
57. 57 DEMOPOULOS, H. B., E. S. FLAMM, D. D. PIETRONIGRO, M. C. SELIGMAN, J. TOMASULA & V. DECRESCITO 1980. The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol. Scand. 492: 91–119.
58. 58 DEMOPOULOS, H. B., E. S. FLAMM, M. C. SELIGMAN, D. D. PIETRONIGRO, J. TOMASULA & V. DECRESCITO 1981. Further studies on free radical pathology in the major central nervous system disorders: Effect of very high doses of methylprednisolone on the functional outcome, morphology and chemistry of experimental spinal cord impact injury. Can. J Physiol. Pharmacol. 60: 1415–1424.
59. 59 BRACKEN, M. B., W. F. COLLINS, D. F. FREEMAN, M. J. SHEPARD, F. W. WAGNER, R. M. SILTEN, K. G. HILLENBRAND, J. RANSOHOFF, W. E. HUNT, P. L. PEROT, R. G. GROSSMAN, B. A. GREEN, N. RIFKINSON, J. H. GOODMAN, J. N. MEAGHER, B. FISCHER, G. L. CLIFTON, E. S. FLAMM & S. E. ROWE 1984. Efficacy of methylprednisolone in acute spinal cord injury. J Am. Med. Assoc. 251: 45–52.
60. 60 BRACKEN, M. B., M. J. SHEPARD, K. G. HELLENBRAND, W. F. COLLINS, L. S. LEO, D. F. FREEMAN, F. C. WAGNER, E. S. FLAMM, H. M. EISENBERG, J. H. GOODMAN, P. L. PEROT, B. A. GREEN, R. G. GROSSMAN, J. N. MEAGHER, W. YOUNG, B. FISCHER, G. L. CLIFTON, W. E. HUNT & N. RIFKINSON 1985. Methylprednisolone and neurological function 1 year after spinal cord injury. J Neurosurg. 63: 704–713.
61. 61 BRAUGHLER, J. M. & E. D. HALL 1983. Uptake and elimination of methylprednisolone from contused cat spinal cord following intravenous infection of the sodium succinate ester. J Neurosurg. 58: 538–542.
62. 62 HALL, E. D. 1985. High‐dose glucocorticoid treatment improves neurological recovery in head‐injured mice. J Neurosurg. 62: 882–887.
63. 63 BRAUGHLER, J. M. & M. J. LAINER 1986. The effects of large doses of methylprednisolone on neurologic recovery and survival in the Mongolian gerbil following three hours of unilateral carotid occlusion. Cent. Nerv. Syst. Trauma 3: 153–161.
64. 64 MASTERS, J. N., C. E. FINCH & R. M. SAPOLSKY 1989. Glucocorticoid endangerment of hippocampal neurons does not involve deoxyribonucleic acid cleavage. Endocrinology 124: 3083–3088.
65. 65 SAPOLSKY, R. M. & W. A. PULSINELLI 1985. Glucocorticoids potentiate ischemic injury to neurons: Therapeutic implications. Science 229: 1397–1400.
66. 66 CHALMERS, D. T., S. P. KWAK, A. MANSOUR, H. AKII & S. J. WATSON 1993. Corticosteroids regulate brain hippocampal 5‐HT1A receptor mRNA expression. J Neurosci. 13: 914–923.
67. 67 YOUNG, W., V. YEN & A. BLIGHT 1982. Extracellular calcium activity in experimental spinal cord contusion. Brain Res. 253: 115–123.
68. 68 DEMEDIUK, P., R. D. SAUNDERS, N. R. CLENDENON, E. D. MEANS, D. K. ANDERSON & L. A. HORROCKS 1985. Changes in lipid metabolism in traumatized spinal cord. Prog. Brain Res. 63: 211–226.
69. 69 HORROCKS, L. A., P. DEMEDIUK, R. D. SAUNDERS, L. DUGAN, N. R. CLENDENON, E. D. MEANS & D. K. ANDERSON 1985. The degradation of phospholipids, formation of metabolites of arachidonic acid, and demyelination following experimental spinal cord injury. Cent. Nerv. Syst. Trauma. 2: 115–120.
70. 70 DEMEDIUK, P., R. D. SAUNDERS, D. K. ANDERSON, E. D. MEANS & L. A. HORROCKS 1985. Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc. Natl. Acad. Sci. USA 82: 7071–7075.
71. 71 SAUNDERS, R. D., L. L. DUGAN, P. DEMEDIUK, E. D. MEANS, L. A. HORROCKS & D. K. ANDERSON 1987. Effects of methylprednisolone and the combination of alpha‐tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue. J Neurochem. 49: 24–31.
72. 72 SORKIN, L. S., J. L. STEINMAN, M. G. HUGHES, W. D. WILLIS & D. J. MCADOO 1988. Microdialysis recovery of serotonin released in spinal cord dorsal horn. J Neurosci. Meth. 23: 131–138.
73. 73 PANTER, S. S., S. W. YUM & A. T. FADER 1990. Alteration in extracellular amino acids after traumatic spinal cord injury. Ann. Neurol. 27: 96–99.
74. 74 LIU, D. X., V. VALADEZ, L. S. SORKIN & D. J. MCADOO 1990. Norepinephrine and serotonin release upon impact injury to rat spinal cord. J Neurotrauma 7: 219–227.
75. 75 SORKIN, L. S., M. G. HUGHES, D. LIU, W. D. J. WILLIS & D. J. MCADOO 1991. Release and metabolism of 5‐hydroxytryptamine in the cat spinal cord examined with microdialysis. J Pharmacol. Exp. Ther. 257: 192–199.
76. 76 FADEN, A. I. 1992. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non‐opioid mechanism. J Neurosci. 12: 425–429.
77. 77 ZHANG, Y., L. HILLERED, Y. OLSSON & A. HOLTZ 1993. Time course of energy perturbation after compression trauma to the spinal cord: An experimental study in the rat using microdialysis. Surg. Neurol. 39: 297–304.
78. 78 YOUNG, W. & I. KOREH 1986. Potassium and calcium changes in injured spinal cords. Brain Res. 365: 42–53.
79. 79 YOUNG, W. 1987. Cellular defenses against excessive Ca entry in brain and spinal cord injury. In Critical Care—State of the Art. F. Cerra, W. Shoemaker, Eds. Fullerton, CA: 71–98. The Society of Critical Care Medicine (251 E. Imperial Highway, Suite 480, Fullerton, CA (92635).
80. 80 YOUNG, W. 1986. Ca paradox in neural injury: A hypothesis. Cent. Nerv. Syst. Trauma. 3: 235–51.
81. 81 ZIMMERMAN, A. N. E. & W. C. HULSMANN 1966. Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat heart. Nature (Lond.). 211: 646–647.
82. 82 ZIMMERMAN, A. N., W. DAKMS, W. C. HULSMAN, J. SNYDER, E. WISSE & D. DORRER 1967. Morphological changes of heart muscle caused by successive perfusion with calcuim‐free and calcium containing solutions. Cardiovasc. Res. 1: 201–209.
83. 83 RUANO‐ARROYO, G., G. GERSTENBLITH & E. G. LAKATTA 1984. Calcium paradox in the heart is modulated by cell sodium during the calcium free period. J Mol. Cell Cardiol. 16: 783–793.
84. 84 NAYLER, W. G., S. E. PERRY, J. S. ELZ & M. J. DALY 1984. Calcium, sodium, and the calcium paradox. Circ. Res. 55: 227–237.
85. 85 BONVALLET, R., O. ROUGIER & Y. TOURNEUR 1984. Role of the Na + ‐Ca 2+ exchange in the calcium paradox in frog auricular trabeculae. J. Mol. Cell. Cardiol. 16: 623–631.
86. 86 SUAREZ, K. G., T. SOLLERO, C. J. H. LEAL & G. KACZOROWSKI 1988. Effects of dichlorobenzamil, a sodium‐calcium exchange inhibitor, on the calcium paradox and the sodium withdrawal contractures of frog atrial muscle. Braz. J Med. Biol. Res. 21: 1197–1211.
87. 87 PIERCE, G. N., T. G. MADDAFORD, E. A. KROEGER & E. J. CRAGOE 1990. Protection by benzamil against dysfunction and damage in rat myocardium after calcium depletion and repletion.. Am J Physiol. 258: H17–23.
88. 88 YOUNG, W. 1992. Role of calcium in central nervous system injuries. J Neurotrauma 9: S9–25.
89. 89 STYS, P. K., B. R. RANSOM, S. G. WAXMAN & P. K. DAVIS 1990. Role of extracellular calcium in anoxic injury of mammalian central white matter. Proc. Natl. Acad. Sci. USA 87: 4212–4216.
90. 90 STYS, P. K., S. G. WAXMAN & B. R. RANSOM 1991. Reverse operation of the Na + ‐Ca 2+ exchanger mediates Ca 2+ influx during anoxia in mammalian CNS white matter. Ann. N. Y. Acad. Sci. 639: 328–332.
91. 91 STYS, P. K., S. G. WAXMAN & B. R. RANSOM 1991. Na + ‐Ca 2+ exchanger mediates Ca 2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol. 30: 375–380.
92. 92 WAXMAN, S. G., B. R. RANSOM & P. K. STYS 1991. Non‐synaptic mechanisms of Ca 2+ ‐mediated injury in CNS white matter. Trends Neurosci. 14: 461–468.
93. 93 STYS, P. K., S. G. WAXMAN & B. R. RANSOM 1992. Ionic mechanisms of anoxic injury in mammalian CNS white matter: Role of Na + channels and Na + ‐Ca 2+ exchanger. J. Neurosci. 12: 430–439.
94. 94 YOUNG, W. 1985. Role of calcium in spinal cord injury. Cent. Nerv. Syst. Trauma 2: 109–114.
95. 95 RAPPAPORT, Z. H., W. YOUNG & E. S. FLAMM 1987. Regional brain calcium changes in the rat middle cerebral artery occlusion model of ischemia. Stroke 18: 760–764.
96. 96 KWO, S., W. YOUNG & V. DECRESCITO 1989. Spinal cord sodium, potassium, calcium, and water concentration changes in rats after graded contusion injury. J Neurotrauma 6: 13–24.
97. 97 MORIYA, T., A. Z. HASSAN, W. YOUNG & M. CHESTER 1994. Dynamics of extracellular calcium activity following contusion of the rat spinal cord. Exp. Neurol. In press.
98. 98 LU, X. & P. M. RICHARDSON 1991. Inflammation near the nerve cell body enhances axonal regeneration. J Neurosci. 11: 972–978.
99. 99 RICHARDSON, P. M. & V. M. VERGE 1987. Axonal regeneration in dorsal spinal roots is accelerated by peripheral axonal transection. Brain Res. 411: 406–408.
100. 100 RICHARDSON, P. M. & V. M. VERGE 1986. The induction of a regenerative propensity in sensory neurons following peripheral axonal injury. J Neurocytol. 15: 585–594.
101. 101 SCHEFF, S. W., L. S. BENARDO & C. W. COTMAN 1980. Hydrocortisone administration retards axon sprouting in the rat dentate gyrus. Exp. Neurol. 68: 195–201.
102. 102 SCHEFF, S. W. & C. W. COTMAN 1982. Chronic glucocorticoid therapy alters axon sprouting in the hippocampal dentate gyrus. Exp. Neurol. 76: 644–654.
103. 103 SCHEFF, S. W. & S. T. DEKOSKY 1983. Steroid suppression of axon sprouting in the hippocampal dentate gyrus of the adult rat: Dose‐response relationship. Exp. Neurol. 82: 183–191.
104. 104 SCHEFF, S. W., S. HOFF & K. J. ANDERSON 1986. Altered regulation of lesioninduced synaptogenesis by adrenalectomy and corticosterone in young adult rats. Exp. Neurol. 93: 456–470.
105. 105 GIANNOTTA, S. L., M. H. WEISS, M. L. APUZZO & E. MARTIN 1984. High dose glucocorticoids in the management of severe head injury. Neurosurgery 15: 497–501.
106. 106 ROBERTSON, C. S., G. L. CLIFTON & J. C. GOODMAN 1985. Steroid administration and nitrogen excretion in the head‐injured patient. J Neurosurg. 63: 714–718.
107. 107 DEMARIA, E. J., W. REICHMAN, P. R. KENNEY, J. M. ARMITAGE & D. S. GANN 1985. Septic complications of corticosteroid administration after central nervous system trauma. Ann. Surg. 202: 248–252.
108. 108 GALANDIUK, S., G. RAQUE, S. APPEL & H. C. POLK, JR. 1993. The twoedged sword of large‐dose steroids for spinal cord trauma. Ann.Surg. 218: 419–425.
109. 109 BLIGHT, A. R. 1992. Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma 9: S83–91.
110. 110 MEANS, E. D., D. K. ANDERSON, P. DEMEDIUK, R. D. SAUNDERS & L. A. HORROCKS 1986. Inflammation in experimental spinal cord injury. Exp. Brain Res. 13: 74–87.
111. 111 BLIGHT, A. R. 1985. Delayed demyelination and macrophage invasion: A candidate for secondary cell damage in spinal cord injury. Cent. Nerv. Syst. Trauma 2: 299–315.
112. 112 HALL, E. D. & J. M. BRAUGHLER 1986. Role of lipid peroxidation in posttraumatic spinal cord degeneration: A review. Cent. Nerv. Syst. Trauma. 3: 281–294.
113. 113 HALL, E. D., P. A. YONKERS, P. K. ANDRUS, J. W. COX & D. K. ANDERSON 1992. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 9: S425–442.
114. 114 BRAUGHLER, J. M. & E. D. HALL 1992. Involvement of lipid peroxidation in CNS injury. J Neurotrauma 9: S1–7.
115. 115 JACOBS, T. P., E. SHOHAMI, W. BAZE, E. BURGARD, C. GUNDERSON, J. HALLENBECK & G. FEUERSTEIN 1987. Thromboxane and 5‐HETE increase after experimental spinal cord injury in rabbits. Cent. Nerv. Syst. Trauma. 4: 95–118.
116. 116 MORELAND, D. B., D. S. SOLONIUK & M. J. FELDMAN 1989. Leukotrienes in experimental spinal cord injury. Surg. Neurol. 31: 277–280.
117. 117 LINDSBERG, P. J., T. L. YUE, K. U. FRERICHS, J. M. HALLENBECK & G. FEUERSTEIN 1990. Evidence for platelet‐activating factor as a novel mediator in experimental stroke in rabbits. Stroke 21: 1452–1457.
118. 118 REBHUN, J., J. G. MADORSKY & M. M. GLOVSKY 1991. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann. Allergy 66: 335–338.
119. 119 FRANCEL, P. C. 1992. Bradykinin and neuronal injury. J Neurotrauma 9: S27–45.
120. 120 DURELLI, L. 1991. Immunotherapeutics of multiple sclerosis. Acta Neurol. 13: 467–475.
121. 121 FRANCIS, D. A. 1993. The current therapy of multiple sclerosis. J Clin. Pharm. Ther. 18: 77–84.
122. 122 LIN, C. Y. 1990. Improvement in steroid and immunosuppressive drug resistant lupus nephritis by intravenous prostaglandin El therapy. Nephron 55: 258–264.
123. 123 BOLTON, W. K. & B. C. STURGILL 1989. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis.. Am J Nephrol. 9: 368–375.
124. 124 ENGEL, T., A. DIRKSEN, L. FROLUND, J. H. HEINIG, U. G. SVENDSEN, B. K. PEDERSEN & B. WEEKE 1990. Methylprednisolone pulse therapy in acute severe asthma. A randomized, double-blind study. Allergy 45: 224–230.
125. 125 SVENNEVIG, J. L. 1987. Blunt chest trauma. Acta Anaesth. Belg. 38: 301–305.
126. 126 SVENNEVIG, J. L. 1991. Diagnosis and management of major trauma. J Neurotrauma 8: S9–12.
127. 127 O'CALLAGHAN, J. P., R. E. BRINTON & B. S. MCEWEN 1991. Glucocorticoids regulate the synthesis of glial fibrillary acidic protein in intact and adrenalectomized rats but do not affect its expression following brain injury. J Neurochem. 57: 860–869.
128. 128 KAWAHARA, R. S., Z. W. DENG & T. F. DEUEL 1991. Glucocorticoids inhibit the transcriptional induction of JE, a platelet‐derived growth factor‐inducible gene. J Biol. Chem. 266: 13261–13266.
129. 129 CARNUCCIO, R., M. DI ROSA, R. J. FLOWER & A. PINTO 1981. The inhibition by hydrocortisone of prostaglandin biosynthesis in rat periotoneal leucocytes is correlated with intracellular macrocortin levels. Br. J Pharmacol. 74: 322–324.
130. 130 HIRATA, F. 1981. The regulation of lipomodulin, a phospholipase inhibitory protein, in rabbit neutrophils by phosphorylation. J Biol. Chem. 256: 7730–7735.
131. 131 HIRATA, F. 1983. Lipomodulin: A possible mediator of the action of glucocorticoids. In Advances in Prostaglandin, Thromboxane and Leukotriene Research. Samuelsson, B., R. Paoletti, P. Ramwell, Eds. 73–78. New York: Raven Press.
132. 132 HIRATA, F. & M. IWATA 1983. Role of lipomodulin phospholipase inhibitory protein, in immunoregulation by thymocytes. J Immunol. 130: 19301936.
133. 133 FLOWER, R. J. 1984. Macrocortin and the mechanisms of action of the glucocorticoids. Adv. Intlamm. Res. 7: 61–68.
134. 134 WALLNER, B. P., R. J. MATTALIANO, C. HESSION, R. L. CATE, R. TIZARD, L. K. SINCLAIR & R. B. PEPINSKY 1986. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti‐inflammatory activity. Nature (Lond.). 320: 77–80.
135. 135 HAIGLER, H. T., D. D. SCHLAEPFER & W. H. BURGESS 1987. Characterisation of lipocortin 1 and an immunologically unrelated 33 kDa protein as epidermal growth factor receptor/kinase substrates and phospholipase A2 inhibitors. J Biol. Chem. 262: 6921–6930.
136. 136 DAVIDSON, F. F., E. A. DENNIS, M. POWELL & J. R. GLENNEY 1987. Inhibition of phospholipase A2 by lipocortin and calpactins—an effect of binding to substrate phospholipids. J Biol. Chem. 262: 1698–1705.
137. 137 SCHLAEPFER, D. D. & H. T. HAIGLER 1987. Characterization of Ca 2+ ‐dependent phospholipid binding and phosphorylation of lipocortin I. J. Biol. Chem. 262: 6931–6936.
138. 138 AARSMAN, A. J., G. MYNBEEK, H. VAN DEN BOSCH, B. ROTHHUT, B. PRIEUR, C. COMERA, L. JORDAN & F. RUSSO‐MARIE 1987. Lipocortin inhibition of extracellular and intracellular phospholipases A2 is substrate concentration independent. FEBS Lett. 219: 176–180.
139. 139 CIRINO, G. & R. J. FLOWER 1987. The inhibitory effect of lipocortin on eicosanoid synthesis is dependent upon Ca 2+ ions. Br. J. Pharmacol. 92: 521P.
140. 140 CIRINO, G., R. J. FLOWER, J. L. BROWNING, L. K. SINCLAIR & R. B. PEPINSKY 1987. Recombinant human lipocortin 1 inhibits thromboxane release from guinea‐pig isolated perfused lung. Nature (Lond.). 328: 270–272.
141. 141 CIRINO, G. & R. J. FLOWER 1987. Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins 34: 59–62.
142. 142 SCHLAEPFER, D. D. & H. T. HAIGLER 1988. In vitro protein kinase C phosphorylation sites of placental lipocortin. Biochemistry 27: 4253–4258.
143. 143 KARASIK, A., R. B. PEPINSKY, S. E. SHOELSON & C. R. KAHN 1988. Lipocortins 1 and 2 as substrates for the insulin receptor kinase in rat liver. J Biol. Chem. 263: 11862–11867.
144. 144 TYERS, M., R. A. RACHUBINSKI, M. I. STEWART, A. M. VARRICHIO, R. G. SHORR, R. J. HASLAM & C. B. HARLEY 1988. Molecular cloning and expression of the major protein kinase C substrate of platelets. Nature (Lond.). 333: 470–473.
145. 145 JOHNSSON, N., G. MARRIOTT & K. WEBER 1988. p36, the major cytoplasmic substrate of src tyrosine protein kinase, binds to its p11 regulatory subunit via a short amino‐terminal amphiphatic helix. Eur. Mol. Biol. Org. J. 7: 2435–2442.
146. 146 KARASIK, A., R. B. PEPINSKY & C. R. KAHN 1988. Insulin and epidermal growth factor stimulate phosphorylation of a 170‐kDa protein in intact hepatocytes immunologically related to lipocortin 1. J Biol. Chem. 263: 18558–18562.
147. 147 BUDAY, L., G. FARKAS & A. FARAGO 1989. The dominant substrate of protein kinase C in the extracts of pig granulocyes is a 38 kDa Ca 2+ ‐membrane binding protein. Acta Biochim. Biophys. Hung. 24: 101–106.
148. 148 ANTONICELLI, F., B. OMRI, M. F. BRETON, B. ROTHHUT, M. F. RUSSO, H. M. PAVLOVIC & B. HAYE 1989. Identification of four lipocortin proteins and phosphorylation of lipocortin 1 by protein kinase C in cytosols of porcine thyroid cell cultures. FEBS Lett. 258: 346–350.
149. 149 WIJKANDER, J. & R. SUNDLER 1989. A role for protein kinase C‐mediated phosphorylation in the mobilization of arachidonic acid in mouse macrophages. Biochim. Biophys. Acta 1010: 78–87.
150. 150 STOEHR, S. J., J. E. SMOLEN & S. J. SUCHARD 1990. Lipocortins are major substrates for protein kinase C in extracts of human neutrophils. J Immunol. 144: 3936–3945.
151. 151 BARNES, J. A., D. MICHIEL & M. D. HOLLENBERG 1991. Simultaneous phosphorylation of three human calpactins by kinase C. Biochem. Cell. Biol. 69: 163–169.
152. 152 PEPINSKY, R. B. 1991. Phosphorylation of lipocortin‐1 by the epidermal growth factor receptor. Methods Enzymol. 198: 260–272.
153. 153 ZHAO, D. Y., K. R. DELL, M. D. HOLLENBERG & D. L. SEVERSON 1991. Phosphorylation of aortic plasma membranes by protein kinase C. Mol. Cell. Biochem. 106: 171–180.
154. 154 JOHNSON, M. D., M. E. GRAY, G. CARPENTER, R. B. PEPINSKY, H. SUNDELL & M. T. STAHLMAN 1989. Ontogeny of epidermal growth factor receptor/kinase and of lipocortin‐1 in the ovine lung. Pediatr. Res. 25: 535–541.
155. 155 JOHNSON, M. D., M. E. GRAY, G. CARPENTER, R. B. PEPINSKY & M. T. SÜAHLMAN 1990. Ontogeny of epidermal growth factor receptor and lipocortin‐1 in fetal and neonatal human lungs. Hum. Pathol. 21: 182–191.
156. 156 ABDEL, G. M., H. K. KOLE, M. A. EL SAAD & E. RACKER 1989. Stimulation of phosphorylation of lipocortin at threonine residues by epidermal growth factor (EGF) and the EGF receptor: Addition of protein kinase P with polylysine inhibits this effect. Proc. Natl. Acad. Sci. USA 86: 6072–6076.
157. 157 KENTON, P., P. M. JOHNSON & P. D. WEBB 1989. The phosphorylation of p68, a calcium‐binding protein associated with the human syncytiotrophoblast submembranous cytoskeleton, is modulated by growth factors, activators of protein kinase C and cyclic AMP. Biochim. Biophys. Acta 1014: 271–281.
158. 158 KREUTER, M. H., R. E. LEAKE, F. RINALDI, K. W. MULLER, A. MAIDHOF, W. E. MULLER & H. C. SCHRODER 1990. Inhibition of intrinsic protein tyrosine kinase activity of EGF‐receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)‐aeroplysinin‐1. Comp. Biochem. Physiol. [B]. 97: 151–158.
159. 159 REVIS, G. S., G. M. ABDEL, J. KOLAND & E. RACKER 1991. Heparin stimulates epidermal growth factor receptor‐mediated phosphorylation of tyrosine and threonine residues. Proc. Natl. Acad. Sci. USA 88: 5954–5958.
160. 160 SHIRAISHI, T., M. K. OWADA, M. TATSUKA, Y. FUSE, K. WATANABE & T. KAKUNAGA 1990. A tyrosine‐specific protein kinase inhibitor, alpha‐cyano‐3‐ethoxy‐4‐hydroxy‐5‐phenylthiomethylcinnamamide, blocks the phosphorylation of tyrosine kinase substrate in intact cells. Jpn. J Cancer Res. 81: 645–652.
161. 161 VARTICOVSKI, L., S. B. CHAHWALA & M. WHITMAN 1988. Location of sites in human lipocortin I that are phosphorylated by protein tyrosine kinases and protein kinases A and C. Biochemistry 27: 3682–3690.
162. 162 JOHNSON, M. D., P. J. KAMSO, R. B. PEPINSKY & W. O. J. WHETSELL 1989. Lipocortin‐1 immunoreactivity in central and peripheral nervous system glial tumors. Hum. Pathol. 20: 772–776.
163. 163 MCKANNA, J. A. 1993. Lipocortin 1 immunoreactivity identifies microglia in adult rat brain. J Neurosci. Res. 36: 491–500.
164. 164 JOHNSON, M. D., M. E. GRAY, R. B. PEPINSKY & M. T. STAHLMAN 1990. Lipocortin‐1 immunoreactivity in the human pituitary gland. J Histochem. Cytochem. 38: 1841–1845.
165. 165 MIELE, L., M. E. CORDELLA, A. FACCHIANO & A. B. MUKHERJEE 1988. Novel anti‐inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature (Lond.). 335: 726–730.
166. 166 NORTHRUP, J. K., K. A. VALENTINE‐BRAUN, L. K. JOHNSON, D. L. SEVERSON & M. D. HOLLENBERG 1988. Evaluation of the anti‐inflammatory and phospholipase‐inhibitory activity of calpactin II/lipocortin I. J Clin. Invest. 82: 1347–1352.
167. 167 CIRINO, G., S. H. PEERS, R. J. FLOWER, J. L. BROWNING & R. B. PEPINSKY 1989. Human recombinant lipocortin 1 has acute local anti‐inflammatory properties in the rat paw edema test. Proc. Natl. Acad. Sci. USA 86: 3428–3432.
168. 168 SOLING, H. D., W. FEST, K. MACHOCZEK, I. SCHMIDT, H. ESELMANN & M. FISCHER 1989. Mechanisms of short‐term (second range) regulation of the activities of enzymes of lipid and phospholipid metabolism in secretory cells. Adv. Enzyme Regul. 28: 35–50.
169. 169 ZHANG, H., Y. C. LI & A. P. YOUNG 1993. Protein kinase A activation of glucocorticoid‐mediated signaling in the developing retina. Proc. Natl. Acad. Sci. USA 90: 3880–3884.
170. 170 CONSTANTINI, S. & W. YOUNG 1994. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg. 80: 97–111.
171. 171 CECCARELLI, F., L. BRACCO & L. BARTOLINI 1976. Effects of gangliosides treatment on functional recovery in experimental regeneration and reinnervation. Adv. Exp. Med. Biol. 71: 275–293.
172. 172 KARPIAK, S. E. 1983. Ganglioside treatment improves recovery of alteration behavior after unilateral entorhinal cortex lesion. Exp. Neurol. 81: 330–339.
173. 173 SABEL, B. A., M. D. SLAVIN & D. G. STEIN 1984. GM‐1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science 225: 340–342.
174. 174 KARPIAK, S. E. 1984. Exogenous gangliosides enhance recovery from CNS injury. In Ganglioside Structure, Function and Biomedical Potential. R. W. Ledeen, R. K. Yu, M. M. Rapport, K. Suzuki, Eds.: 489–494. New York: Plenum Publishing.
175. 175 KARPIAK, S. E., Y. S. LI & S. P. MAHADIK 1987. Ganglioside treatment: Reduction of CNS injury and facilitation of functional recovery. Brain Inj. 1: 161–70.
176. 176 KARPIAK, S. E., Y. S. LI & S. P. MAHADIK 1987. Gangliosides (GM1 and AGF2) reduce mortality due to ischemia: Protection of membrane function. Stroke 18: 184–187.
177. 177 GEISLER, F. H., F. C. DORSEY & W. P. COLEMAN 1991. Recovery of motor function after spinal‐cord injury—a randomized, placebo‐controlled trial with GM‐1 ganglioside. New Engl. J Med. 324: 1829–1838.
178. 178 SKAPER, S. D. & A. LEON 1992. Monosialogangliosides, neuroprotection, and neuronal repair processes. J Neurotrauma 2: S507–516.
179. 179 SCHNEIDER, J. S., A. POPE, K. SIMPSON, J. TAGGART, M. G. SMITH & L. DISTEFANO 1992. Recovery from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 256: 843–846.
180. 180 GOLDENRING, J. R., L. C. OTIS, R. K. YU & R. J. DELORENZO 1985. Calcium/ganglioside‐dependent protein kinase activity in rat brain membrane. J Neurochem. 44: 1129–1134.
181. 181 KREUTTER, D., J. Y. H. KIM, J. R. GOLDENRING, H. RASMUSSEN, C. UKOMADO, R. DELORENZO & R. K. YU 1987. Regulation of protein kinase C activity by gangliosides. J Biol. Chem. 262: 1633–1637.
182. 182 KIM, J. Y. H., J. R. GOLDENRING, R. DELORENZO & R. K. YU 1986. Gangliosides inhibit phospholipid‐sensitive Ca 2+ ‐dependent kinase phosphorylation of rat myelin basic protein. J. Neurosci. Res. 15: 159–166.
183. 183 VACCARINO, F., A. GUIDOTTI & E. COSTA 1987. Ganglioside inhibition of glutamate‐mediated protein kinase C translocation in primary cultures of cerebellar neurons. Proc. Natl. Acad. Sci. USA 84: 8707–8711.
184. 184 CHAN, K. F. J. 1988. Gangliosides modulate protein phosphorylation. Partial purification and characterization of a ganglioside‐stimulated protein kinase in brain. J Biol. Chem. 263: 568–574.
185. 185 YATES, A. J., J. D. WALTERS, C. L. WOOD & J. D. JOHNSON 1989. Ganglioside modulation of cyclic AMP‐dependent protein kinase and cyclic nucleotide phosphodiesterase in vitro. J Neurochem. 53: 162–167.
186. 186 XIA, X. J., X. B. GU, A. C. SARTORELLI, R. K. YU & A. C. SANTORELLI 1989. Effects of inducers of differentiation on protein kinase C and CMPN‐acetylneuraminic acid: Lactosylceramide sialytransferase activities of HL‐60 leukemia cells. J Lipid Res. 30: 181–188. Published erratum appears in J. Lipid Res. 1989 (Apr) 30 (4): 631.
187. 187 SPIEGEL, S. 1989. Inhibition of protein kinase C‐dependent cellular proliferation by interaction of endogenous ganglioside GM1 with the B subunit of cholera toxin. J Biol. Chem. 264: 16512–16517.
188. 188 MORRISON, W. J., H. OFFNER & A. A. VANDENBARK 1990. Transmembrane signalling associated with ganglioside‐induced CD4 modulation. Immuno-pharmacology 20: 135–41.
189. 189 FUKUNAGA, K., E. MIYAMOTO & T. R. SODERLING 1990. Regulation of Ca 2+ /calmodulin‐dependent protein kinase II by brain gangliosides. J. Neurochem. 54: 103–109.
190. 190 MAGAL, E., J. C. LOUIS, J. AGUILERA & E. YAVIN 1990. Gangliosides prevent ischemia‐induced down‐regulation of protein kinase C in fetal rat brain. J Neurochem. 55: 2126–2131.
191. 191 HILBUSH, B. S. & J. M. LEVINE 1991. Stimulation of a Ca 2+ ‐dependent protein kinase by GM1 ganglioside in nerve growth factor‐treated PC12 cells. Proc. Natl. Acad. Sci. USA 88: 5616–5620.
192. 192 NORDEEN, S. K., M. L. MOYER & B. J. BONA 1994. The coupling of multiple signal transduction pathways with steroid response mechanisms. Endocrinology 134: 1723–1732.
193. 193 CAMPOS, S. P. & H. BAUMANN 1992. Insulin is a prominent modulator of the cytokine‐stimulated expression of acute‐phase plasma protein genes. Mol. Cell. Biol. 12: 1789–1797.
194. 194 SPIEGEL, S. & P. H. FISHMAN 1987. Gangliosides as bimodal regulators of cell growth. Proc. Natl. Acad. Sci. USA 84: 141–145.
195. 195 ZOR, U., E. HER, T. HARELL, G. FISCHER, Z. NAOR, P. BRAQUET, E. FERBER & N. REISS 1991. Arachidonic acid release by basophilic leukemia cells and macrophages stimulated by Ca 2+ ionophores, antigen and diacylglycerol: Essential role for protein kinase C and prevention by glucocorticosteroids. Biochim. Biophys. Acta 1091: 385–392.
196. 196 KAWAI, H., M. OHGOH, S. EMOTO, E. OHMORI, N. IMANISHI, K. YATSUNAMI & S. ICHIKAWA 1991. Synergistic effects of 12‐O‐tetradecanoylphorbol‐13‐acetate and dexamethasone on de novo synthesis of histidine decarboxylase in mouse mastocytoma P‐815 cells. Biochim. Biophys. Acta 1133: 172–178.
197. 197 ORTI, E., J. E. BODWELL & A. MUNCK 1992. Phosphorylation of steroid hormone receptors. Endocr. Rev. 13: 105–128.
198. 198 HSU, S. C., M. QI & D. B. DEFRANCO 1992. Cell cycle regulation of glucocorticoid receptor function. Eur. Mol. Biol. Org. J. 11: 3457–3468.
199. 199 SALMON, J. E., S. KAPUR, N. L. MERYHEW, O. A. RUNQUIST & R. P. KIMBERLY 1989. High‐dose, pulse intravenous methylprednisolone enhances Fc gamma receptor‐mediated mononuclear phagocyte function in systemic lupus erythematosus. Arthritis Rheum. 32: 717–725.
200. 200 SAWADA, S., G. SUZUKI, Y. KAWASE & F. TAKAKU 1987. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 139: 1797–1803.
201. 201 STARZL, T. E., S. TODO, J. FUNG, A. J. DEMETRIS, R. VENKATARAMMAN & A. JAIN 1989. FK506 for liver, kidney, and pancreas transplantation. Lancet 2: 1000–1004.
202. 202 LIU, J., J. D. FARMER, W. S. LANE, J. FRIEDMAN, I. WEISSMAN & S. L. SCHREIBER 1991. Calcineurin is a common target of cyclophilin‐cyclosporin A and FKBP‐FK506 complexes. Cell 66: 807–815.
203. 203 LIU, J., J. D. J. FARMER, W. S. LANE, J. FRIEDMAN, I. WEISSMAN & J. L. SCHREIBER 1992. Inhibition of T cell signalling by immunophilin‐ligand complex correlates with loss of calcineurin phosphatase activity. Biochemistry 31: 3896–3901.
204. 204 BIERER, B. E., P. S. MATTILA, R. F. STANDAERT, L. A. HERZENBERG, S. J. BURAKOFF, G. CRABTREE & S. L. SCHREIBER 1990. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 87: 9231–9235.
205. 205 LIU, J. 1993. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol. Today 14: 290–295.
206. 206 SCHREIBER, S. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283–287.
207. 207 SCHREIBER, S. L. & G. R. CRABTREE 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13: 136–142.
208. 208 STEINER, J. P., T. M. DAWSON, M. SOTUHI, C. E. GLATT, A. M. SNOWMAN, N. COHEN & S. H. SNYDER 1992. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature (Lond.). 358: 584–587.
209. 209 CALLEBAUT, I., J. M. RENOIR, M. C. LEBEAU, N. MASSOL, A. BURNEY, E. E. BAULIEU & J. P. MORNON 1992. An immunophilin that binds M(r) 90,000 heat shock protein: Main structural features of a mammalian p59 protein. Proc. Natl. Acad. Sci. USA 89: 6270–6274.
210. 210 TAI, P. K., M. W. ALBERS, H. CHANG, L. E. FABER & S. L. SCHREIBER 1992. Association of a 59‐kilodalton immunophilin with the glucocorticoid receptor complex. Science 256: 1315–1318.
211. 211 KUNZ, J. & M. N. HALL 1993. Cyclosporin A, FK506 and rapamycin: More than just immunosuppression. Trends Biochem. Sci. 18: 334–338.
212. 212 EDWARDS, S. N. & A. M. TOLKOVSKY 1994. Characterization of apoptosis in cultured rat sympathetic neurons after nerve growth factor withdrawal. J Cell Biol. 124: 537–546.
213. 213 RATAN, R. R., T. H. MURPHY & J. M. BARABAN 1994. Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem. 62: 376–379.
214. 214 DIANA, A., M. SETZU, S. SIRIGU & G. DIAZ 1993. Nuclear patterns of apoptotic and developing neurons of superior cervical ganglion of newborn rat. Int. J Dev. Neurosci. 11: 773–780.
215. 215 LINNIK, M. D., R. H. ZOBRIST & M. D. HATFIELD 1993. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 24: 2002–2008.
216. 216 LINNIK, M. D., M. D. HATFIELD, M. D. SWOPE & N. K. AHMED 1993. Induction of programmed cell death in a dorsal root ganglia X neuroblastoma cell line. J Neurobiol. 24: 433–446.
217. 217 ENOKIDO, Y. & H. HATANAKA 1993. Apoptotic cell death occurs in hippocampal neurons cultured in a high oxygen atmosphere. Neuroscience 57: 965–972.
218. 218 JOSEPH, R., W. LI & E. HAN 1993. Neuronal death, cytoplasmic calcium and internucleosomal DNA fragmentation: Evidence for DNA fragments being released from cells. Brain Res. Mol. Brain Res. 17: 70–76.
219. 219 KESSLER, J. A., W. H. LUDIAM, M. M. FREIDIN, D. H. HALL, M. D. MICHAELSON, D. C. SPRAY, M. DOUGHERTY & D. K. BATTER 1993. Cytokine‐induced programmed death of cultured sympathetic neurons. Neuron 11: 1123–1132.
220. 220 DECKWERTH, T. L. & E. M. JOHNSON, JR. 1993. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J Cell Biol. 123: 1207–1222.
221. 221 D'MELLO, S. R., C. GALLI, T. CIOTTI & P. CALISSANO 1993. Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin‐like growth factor I and cAMP. Proc. Natl. Acad. Sci. USA 90: 10989–10993.
222. 222 CAIRNS, J. S., M. S. MAINWARING, R. N. CACCHIONE, J. A. WALKER & S. A. MCCARTHY 1993. Regulation of apoptosis in thymocytes. Thymus 21: 177–193.
223. 223 MAILHOS, C., M. K. HOWARD & D. S. LATCHMAN 1993. Heat shock protects neuronal cells from programmed cell death by apoptosis. Neuroscience 55: 621–627.
224. 224 LOO, D. T., A. COPANI, C. J. PIKE, E. R. WHITTEMORE, A. J. WALENCEWICZ & C. W. COTMAN 1993. Apoptosis is induced by beta‐amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 90: 7951–7955.
225. 225 GOULD, E. & B. S. MCEWEN 1993. Neuronal birth and death. Curr. Opin. Neurobiol. 3: 676–682.
226. 226 PITTMAN, R. N., S. WANG, A. J. BIBENEDETTO & J. C. MILLS 1993. A system for characterizing cellular and molecular events in programmed neuronal cell death. J Neurosci. 13: 3669–3680.
227. 227 WEEKS, J. C., S. K. DAVIDSON & B. H. DEBU 1993. Effects of a protein synthesis inhibitor on the hormonally mediated regression and death of motoneurons in the tobacco hornworm, Manduca sexta. J Neurobiol. 24: 125–40. Published erratum appears in J. Neurobiol. 1993 (Mar). 24 (3): 419.
228. 228 SHI, Y. F., B. M SAHAI & D. R. GREEN 1989. Cyclosporin A inhibits activation‐induced cell death in T‐cell hybridomas and thymocytes. Nature (Lond.). 339: 625–626.
229. 229 SHI, Y. F., M. G. SZALAI, L. PASKAR, B. M SAHAT, M. BOYER, B. SINGH & D. R. GREEN 1990. Activation‐induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. J Immunol. 144: 3326–3333. Published erratum appears in J. Immunol. 1990 (Dec 1) 145 (11): 3945.
230. 230 FRUMAN, D. A., P. E. MATHER, S. J. BURAKOFF & B. E. BIERER 1992. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. Eur. J Immunol. 22: 2513–2517.
231. 231 MCCARTHY, S. A., R. N. CACCHIONE, M. S. MAINWARING & J. S. CAIRNS 1992. The effects of immunosuppressive drugs on the regulation of activation‐induced apoptotic cell death in thymocytes. Transplantation 54: 543–547.
232. 232 LITTLE, G. H. & A. FLORES 1992. Inhibition of programmed cell death by cyclosporin. Comp. Biochem. Physiol. [C]. 103: 463–467.
233. 233 GROUX, H., D. MONTE, B. PLOUVIER, A. CAPRON & J. C. AMEISEN 1993. CD3‐mediated apoptosis of human medullary thymocytes and activated peripheral T cells: Respective roles of interleukin‐1, interleukin‐2, interferon‐gamma and accessory cells. Eur. J Immunol. 23: 1623–1629.
234. 234 BONNEFOY‐BERARD, N., L. GENESTIER, M. FLACHER & J. P. REVILLARD 1994. The phosphoprotin phosphatase calcineurin controls calcium‐dependent apoptosis in B cell lines. Eur. J Immunol. 24: 325–329.
235. 235 DAWSON, T. M., J. P. STEINER, V. L. DAWSON, J. L. DINERMAN, G. R. UHL & S. H. SNYDER 1993. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity [see comments]. Proc. Natl. Acad. Sci. USA 90: 9808–9812.
236. 236 DAWSON, V. L., T. M. DAWSON, E. D. LONDON, D. S. BREDT & S. H. SNYDER 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88: 6368–6371.
237. 237 SNYDER, S. H. & D. S. BREDT 1991. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12: 125–128.
238. 238 BUISSON, A., M. PLOTKINE & R. G. BOULU 1992. The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. Br. J Pharmacol. 106: 766–767.
239. 239 DAWSON, D. A., K. KUSUMOTO, D. I. GRAHAM, J. MCCULLOCH & I. M. MACRAE 1992. Inhibition of nitric oxide synthesis does not reduce infarct volume in a rat model of focal cerebral ischaemia. Neurosci. Lett. 142: 151–154.
240. 240 NAGAFUJI, T., T. MATSUI, T. KOIDE & T. ASANO 1992. Blockade of nitric oxide formation by N omega‐nitro‐L‐arginine mitigates ischemic brain edema and subsequent cerebral infarction in rats. Neurosci. Lett. 147: 159–162.
241. 241 YAMAMOTO, S., E. V. GOLANOV, S. B. BERGER & D. J. REIS 1992. Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat. J Cereb. Blood Flow Metab. 12: 717–726.
242. 242 MORIKAWA, E., S. ROSENBLATT & M. A. MOSKOWITZ 1992. L‐arginine dilates rat pial arterioles by nitric oxide‐dependent mechanisms and increases blood flow during focal cerebral ischaemia. Br. J Pharmacol. 107: 905–907.
243. 243 HOLDER, M. J., K. KNOX & J. GORDON 1992. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor‐beta, but not cyclosporin A or anti‐CD19, block surface immunoglobulin‐mediated rescue from apoptosis. Eur. J Immunol. 22: 2725–2728.